Biotechnology
Kelun-Biotech Announces Interim Results for 2023: Global Strategic Partnership and Rich Pipeline Boost Significant Revenue Growth in the First Half of the Year
CHENGDU, China, Aug. 28, 2023 /PRNewswire/ -- Today, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990.HK), an innovative biopharmaceutical company focusing on the R&D, manufacturing, commercialization, and international cooperation of biotechnology drugs and innovat...
2023-08-28 22:56
3344
Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines
The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject® (ferric carboxymaltose), for the management of iron deficiency in patients with HF. Phase IV HEART-FI...
2023-08-28 19:00
2019
Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline
SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its interim results for the six-months endedJune 30, 2023, and provided updates on multiple milestones achieved since the beginning of 2023. Dr. Jay Mei, Antengene's F...
2023-08-25 19:37
2109
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth
SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits ofRMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products. HANQUYOU (trast...
2023-08-25 19:26
5228
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximatelyRMB3,783.8 million, up 22.3% on a yearly basis. Gross profit was approximatelyRMB3,201.6 million, up ...
2023-08-25 10:06
4044
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy
SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Everest Medicines
2023-08-25 08:15
1966
Antheia Achieves Major Commercial Milestone
Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMs and APIs MENLO PARK, Calif., Aug. 25, 2023 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the...
2023-08-25 08:01
1772
YS Biopharma Announces Purchase of Shares by Company Officers
GAITHERSBURG, Md., Aug. 25, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2023-08-25 04:15
2087
Everest Medicines Announces Interim Results for First Half of 2023
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, ...
2023-08-24 08:15
3558
Salvia BioElectronics: First-Ever Patient Treated with Breakthrough Neuromodulation Solution for Severe Migraine and Cluster Headache in Australia
NAMBOUR, Australia, Aug. 24, 2023 /PRNewswire/ -- In a remarkable medical milestone, an Australian patient at Nambour Selangor Private Hospital became the first-ever patient to receive Salvia BioElectronics' paper-thin neuromodulation solution for severe migraine and cluster headache. This groun...
2023-08-24 05:45
1495
MGI Partners with NGeneBio to Advance Precision Medicine
SEOUL, South Korea, Aug. 23, 2023 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science and NGeneBio, a company specializing in next-generation sequencing-based diagnostic have signed a memorandum of understanding (MOU) to expand the commercial access...
2023-08-23 09:00
2103
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end ...
2023-08-22 22:00
2949
Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" Designated Therapy for Treatment of All Subtypes of Epidermolysis Bullosa (EB)
'Topical Therapy for Treating the Wounds and Lesions on the Entire Skin Surface' MT PLEASANT, S.C., Aug. 22, 2023 /PRNewswire/ -- Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the completion of the acquisition of the worldwide rights of SD-101, a topical whole-body trea...
2023-08-22 21:13
1894
Hummingbird Bioscience to Present Poster on HMBD-001 Combination Strategy for Squamous Non-Small Cell Lung Cancer at World Conference on Lung Cancer 2023
HOUSTON and SINGAPORE, Aug. 21, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at the IASLC 2023 World Conference ...
2023-08-21 17:58
1324
3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling
REYKJAVIK, Iceland and BERLIN, Aug. 18, 2023 /PRNewswire/ -- Reykjavik-based drug discovery company, 3Z, andGermany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the ...
2023-08-18 22:45
2653
QiLu Pharmaceutical's Iruplinalkib Phase III INSPIRE Study Researched Primary Endpoint and was Selected for 2023 WCLC Oral Presentation
JINAN, China, Aug. 18, 2023 /PRNewswire/ -- August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical's iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral presentation at th...
2023-08-18 09:50
2261
Novo Holdings participates in $290m strategic financing of Sangon Biotech
COPENHAGEN, Denmark, Aug. 17, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced it has participated in a $290 million (USD) strategic financing round of Sangon Biotech. Sangon is a leading provider of life science tools and services, enabling scient...
2023-08-17 09:44
1949
Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2023-08-17 08:00
2885
Oncoclínicas Group generated record earnings in the second quarter of 2023, R$309 million and a net profit of R$35 million
Efficient management of working capital explains a large part of the cash flow performance. Net income grew 51% (31% organically) while the Ebitda Ex-LTIP (excluding only the non-cash impact of the long-term incentive plan) reached R$268 million, 109% greater than the same period last year SÃO PA...
2023-08-16 19:00
1642
MGI Unveils Latest MGISP-NEX and MGIFLP-L50 Automation Systems at Medlab Asia & Asia Health 2023
BANGKOK, Thailand, Aug. 16, 2023 /PRNewswire/ -- MGI, a company committed to building core tools and technology to lead life science, today announced the global launch of MGISP-NEX and MGIFLP-L50 automation platforms at Medlab Asia & Asia Health 2023, taking place from 16-18 August at IMPACT E...
2023-08-16 11:00
2142
Week's Top Stories
Most Reposted
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 318 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 301 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 272 media titles]
2024-05-16 09:39
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
[Picked up by 272 media titles]
2024-05-10 15:20
Where does China's production capacity come from?
[Picked up by 258 media titles]
2024-05-10 12:01Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
8601
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
2024-05-10 15:20
7969
Where does China's production capacity come from?
2024-05-10 12:01
7807
China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering
2024-05-10 21:20
4977